Johnson & Johnson news – The Milli Chronicle

Friday, October 10, 2025

Latest:

Saudi Post Strengthens Global Logistics and Supports Vision 2030
Saudi Philanthropist Rania Moualla Honored Globally for Transformative Culinary Education and Social Impact
U.S. Sanctions Aim to Streamline Global Energy Trade and Boost Market Transparency
Europeans and Arabs Unite to Build a Stable, Post-War Gaza
Tesla Revives Europe’s EV Excitement with Affordable Model Y Standard — Innovation Meets Accessibility!

Factual Version of a Story

Featured Health Lifestyle

NewsDesk Milli Chronicle October 10, 2025 biotech mergers 2025, biotechnology acquisition, drug development news, global biotech investments, healthcare innovation, J&J biotech expansion, J&J pharma growth, Janssen Biotech collaboration, Johnson & Johnson acquisition, Johnson & Johnson news, Johnson & Johnson strategy., medical research, peptide-based drugs, pharmaceutical innovation, polycythemia vera treatment, Protagonist stock surge, Protagonist Therapeutics, rare disease therapy, Rusfertide PTG-300, WSJ report

Johnson & Johnson Eyes Major Leap in Biotech: Talks Underway to Acquire Protagonist Therapeutics in Billion-Dollar Move

In a bold bid to expand its cutting-edge drug pipeline, Johnson & Johnson is reportedly in advanced talks to acquire